Your browser doesn't support javascript.
loading
In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.
Tjin Tham Sjin, Robert; Lee, Kwangho; Walter, Annette O; Dubrovskiy, Aleksandr; Sheets, Michael; Martin, Thia St; Labenski, Matthew T; Zhu, Zhendong; Tester, Richland; Karp, Russell; Medikonda, Aravind; Chaturvedi, Prasoon; Ren, Yixuan; Haringsma, Henry; Etter, Jeff; Raponi, Mitch; Simmons, Andrew D; Harding, Thomas C; Niu, Deqiang; Nacht, Mariana; Westlin, William F; Petter, Russell C; Allen, Andrew; Singh, Juswinder.
Affiliation
  • Tjin Tham Sjin R; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California rtjin@celgene.com.
  • Lee K; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Walter AO; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Dubrovskiy A; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Sheets M; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Martin TS; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Labenski MT; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Zhu Z; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Tester R; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Karp R; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Medikonda A; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Chaturvedi P; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Ren Y; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Haringsma H; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Etter J; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Raponi M; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Simmons AD; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Harding TC; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Niu D; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Nacht M; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Westlin WF; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Petter RC; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Allen A; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
  • Singh J; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
Mol Cancer Ther ; 13(6): 1468-79, 2014 Jun.
Article de En | MEDLINE | ID: mdl-24723450
Sujet(s)
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: 4-Amino-pyridine / Carcinome pulmonaire non à petites cellules / Récepteurs ErbB / Récidive tumorale locale Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Mol Cancer Ther Sujet du journal: ANTINEOPLASICOS Année: 2014 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: 4-Amino-pyridine / Carcinome pulmonaire non à petites cellules / Récepteurs ErbB / Récidive tumorale locale Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Mol Cancer Ther Sujet du journal: ANTINEOPLASICOS Année: 2014 Type de document: Article